Bandhan Healthcare Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?

Bandhan Healthcare Fund Direct Growth Plan had a NAV of ₹11.237 as of 16 September 2026 and scheme AUM of ₹331 Cr. Its 1-year, 3-year and 5-year returns are 0%, 0% and 0%, and the fund is tagged as High Risk.

Our view is that this is still a young healthcare-focused scheme, so the return record is too short to judge it through a full cycle. The recent numbers and the portfolio make it more suitable for investors who can tolerate sharp swings and want a focused sector exposure rather than a diversified core holding.

Quick facts

Particular	Details
NAV	₹11.237 as of 16 Sep 2026
AUM	₹331 Cr
Expense Ratio	0.0%
Launch Date	28 Nov 2025
Min SIP	₹100
Risk Category	High Risk
Benchmark	Nifty 50
Exit Load	0.50% on or before 30D, Nil after 30D
Fund Managers	Viraj Kulkarni, Brijesh Shah, Ritika Behera, Gaurav Satra

The fund is managed by Viraj Kulkarni, Brijesh Shah, Ritika Behera and Gaurav Satra.

Source data date: as of 16 Sep 2026

Performance

Period	Fund return	Benchmark return
1M	-0.64%	-4.41%
3M	8.26%	-3.6%
1Y	Data not available	Data not available
3Y	Data not available	Data not available
5Y	Data not available	Data not available

The short-horizon pattern is mixed but constructive. Over one month, the fund was slightly negative while the benchmark was more weakly negative, which means the scheme did not fully escape the market pressure but held up better than the index in that window.

The three-month picture is stronger. The fund returned 8.26% while the benchmark fell 3.6%, so the scheme clearly outpaced the index over that stretch. That gap suggests the portfolio has been able to benefit from healthcare-specific moves even when the broader market was softer.

Because the scheme launched only in November 2025, longer trailing periods are not yet available in a meaningful way. That makes the available history useful for short-term reading, but not enough to build confidence in a full-cycle return pattern. For now, the main takeaway is that near-term behaviour has been better than the benchmark, but the record is still limited.

Source data date: as of 16 Sep 2026

Should you BUY or HOLD Bandhan Healthcare?

A fund's past returns alone don't tell you whether you should buy it today or continue holding it.

The right decision depends on factors such as your current allocation, purchase price, risk profile, investment horizon and the role this fund plays in your overall portfolio.

Already holding Bandhan Healthcare? Thinking of investing now?

Get your portfolio analysed for FREE by SEBI-registered Investment Adviser (RIA) through Univest MF Premium

Peer comparison

Fund	1Y return	3Y return	5Y return
Bandhan Healthcare Fund Direct Growth Plan	Data not available	Data not available	Data not available
Baroda BNP Paribas Gold ETF FoF Direct Growth Plan	34.39%	Data not available	Data not available
HDFC Innovation Fund Direct Growth Plan	14.3%	Data not available	Data not available
Bajaj Finserv Small Cap Fund Direct Growth Plan	13.33%	Data not available	Data not available
Quant Equity Savings Fund Direct Growth Plan	8.75%	Data not available	Data not available
Kotak Active Momentum Fund Direct Growth Plan	6.31%	Data not available	Data not available

This assessment is prepared by Uniapps Investment Adviser Pvt. Ltd. under SEBI Registered Investment Adviser registration INA000017639.

The fund has no available 1-year trailing return to compare directly with the peer set, while the listed peers show clearly positive 1-year figures. That means the comparison is more useful for context than for a strict like-for-like judgment.

Where the fund does have usable history, the 3-month reading is stronger than the peer figures shown for their 1-year horizons only in the sense that it has beaten the benchmark over that short window, but the peer table does not give a matching 3-month lens. On available 1-year peer numbers, the fund does not yet present a return figure that can be lined up against them.

Because the other schemes also show no available 3-year or 5-year data in this table, the short-term story is stronger than the long-term comparison set here. The main message is that the fund’s track record is still too short for a deep comparison, even though its recent performance has been better than the benchmark.

Source data date: as of 16 Sep 2026

Portfolio: where your money goes

Holding	Sector	Weight
Sun Pharmaceutical Industries Limited	Healthcare	10.48%
Cipla Limited	Healthcare	6.38%
Max Healthcare Institute Limited	Healthcare	5.81%
Apollo Hospitals Enterprise Limited	Healthcare	5.64%
Triparty Repo TRP_010926	Cash & Cash Equivalents and Net Assets	4.33%
Divi'S Laboratories Limited	Healthcare	4.28%
Aurobindo Pharma Limited	Healthcare	4.14%
Lupin Limited	Healthcare	3.96%
Shilpa Medicare Limited	Healthcare	3.72%
Glaxosmithkline Pharmaceuticals Limited	Healthcare	3.68%

The top 10 holdings account for approximately 52.42% of the portfolio.

To see all holdings, visit the Bandhan Healthcare Fund Direct Growth Plan page

The largest holding, Sun Pharmaceutical Industries Limited, carries a 10.48% weight, which is large enough to matter on its own but not so large that it dominates the entire portfolio. The tenth holding still sits at 3.68%, so the drop from the first to the tenth position is noticeable but not extreme.

That shape suggests a portfolio that is still fairly concentrated in a small set of names, especially because the top 10 holdings together account for 52.42% of the portfolio and the scheme discloses 36 holdings overall. The remaining positions likely create a longer tail of smaller exposures, which may reduce single-stock dependence.

At the same time, the healthcare theme is visible across the table, so the fund may be more sensitive to moves within that sector than a diversified equity fund. The cash and cash-equivalent holding also adds a modest stabilising element, but the overall setup still points to a focused portfolio rather than a broad market basket.

Source data date: as of 16 Sep 2026

Who should invest

This fund suits investors who can tolerate High Risk and are comfortable with a narrow sector focus. The limited history means it is better viewed as a healthcare allocation with a short performance record rather than a long-established core holding.

The available returns suggest that near-term behaviour can differ from the broader market, and the benchmark comparison shows that the fund has been able to outpace the index in the recent three-month window. The trade-off is clear: investors may get stronger sector-led upside when healthcare is supportive, but they also accept a more concentrated path of returns and a shorter track record.

Tax and exit load

Holding period	Tax rate	Description
Units held less than 1 year	20%	Short-term capital gains tax
Units held more than 1 year	12.5%	Long-term capital gains tax

Exit load: 0.50% if units are sold on or before 30 days; nil after 30 days.

Source data date: as of 16 Sep 2026

Frequently asked questions

What is the current NAV of Bandhan Healthcare Fund Direct Growth Plan?
The current NAV is ₹11.237 as of 16 September 2026.

What are the fund’s recent returns?
The fund’s 1-month return is -0.64% and its 3-month return is 8.26%. The 1-year, 3-year and 5-year figures are not available for this scheme.

How has the fund performed versus the benchmark?
It has done better than the benchmark over 3 months, where the fund returned 8.26% and the benchmark returned -3.6%. Over 1 month, the fund was -0.64% versus -4.41% for the benchmark.

How does the fund compare with peers on available return data?
The peer table shows 1-year gains for the other named funds, while this scheme does not yet have a usable 1-year trailing return. That makes the comparison more useful for context than for a direct like-for-like conclusion.

Is there a minimum SIP?
Yes, the minimum SIP is ₹100.

What should investors know about the risk and portfolio?
The fund is tagged High Risk, and its largest holding is Sun Pharmaceutical Industries Limited at 10.48%. The top 10 holdings together account for 52.42% of the portfolio, so the scheme remains fairly focused.

Bottom line

Bandhan Healthcare Fund Direct Growth Plan has shown a better recent stretch than the benchmark, but the longer record is still too short to judge it across full market cycles. On the available comparison set, its return history is less developed than the peer figures shown, so the main draw is the sector-focused portfolio rather than an established long-term track record. The fund remains High Risk, and the top holdings carry enough weight that stock selection is likely to matter.

Published on 17 September 2026 at 12:44 PM IST

Explore mutual funds with Univest

Review mutual fund data, compare performance and explore fund insights on Univest.

Explore Univest

RIA disclosure

Mutual fund investments are subject to market risks. Read all scheme-related documents carefully before investing. This review is prepared by Uniapps Investment Adviser Pvt. Ltd. (earlier known as Uniapps Global Research Pvt. Ltd.) under SEBI Registered Investment Adviser registration INA000017639 for general informational purposes and is not personalized investment advice.